| Literature DB >> 31324020 |
Fariba Mollarasouli1,2, Sevinc Kurbanoglu1, Sibel A Ozkan3.
Abstract
An immunosensor is a kind of affinity biosensor based on interactions between an antigen and specific antigen immobilized on a transducer surface. Immunosensors possess high selectivity and sensitivity due to the specific binding between antibody and corresponding antigen, making them a suitable platform for several applications especially in the medical and bioanalysis fields. Electrochemical immunosensors rely on the measurements of an electrical signal recorded by an electrochemical transducer and can be classed as amperometric, potentiometric, conductometric, or impedimetric depending on the signal type. Among the immunosensors, electrochemical immunosensors have been more perfected due to their simplicity and, especially their ability to be portable, and for in situ or automated detection. This review addresses the potential of immunosensors destined for application in clinical analysis, especially cancer biomarker diagnosis. The emphasis is on the approaches used to fabricate electrochemical immunosensors. A general overview of recent applications of the developed electrochemical immunosensors in the clinical approach is described.Entities:
Keywords: biomarker; clinical analysis; electrochemistry; immunosensors; label free; labeled
Year: 2019 PMID: 31324020 PMCID: PMC6784381 DOI: 10.3390/bios9030086
Source DB: PubMed Journal: Biosensors (Basel) ISSN: 2079-6374
Figure 1Schematic diagram of the electrochemical biosensor array. The bioassay is carried out using the working electrodes of the array as transducers and in situ electrochemical detection of QDs. Reprinted with Permission [22].
Figure 2Schematic representation of (A) competitive and (B) non-competitive immunoassay formats. Reprinted with Permission [35].
Figure 3The schematic illustration of the dual mode competitive electrochemical immunosensor. Reprinted with Permission [38].
Figure 4Schematic representation of Fullerene-Functionalized Carbon Nanotubes/Ionic Liquid based label-free electrochemical immunosensor. Reprinted with Permission [75].
Figure 5The schematic illustration of the sandwich-type electrochemical immunosensor and the preparation procedure of Au@N-GQDs NPs and Au@Ag-Cu2O/Ab2 Reprinted with Permission [82].
Some selected studies on electrochemical immunosensors in clinical analyses.
| Biomarker | Type of Illness | Immunosensor | Electrochemical Technique | Linear Range | LOD | Reference | |
|---|---|---|---|---|---|---|---|
| AFP | Liver, Ovarian, Testicular Cancers | Nanogold/TH- | Amperometry | 0.1–200 ng·mL−1 | 0.05 ng·mL−1 | [ | |
| AFP | Liver, Ovarian, Testicular cancers | AuNPs/graphene-doped CS/TH-GCE | Amperometry | 1–10 ng·mL−1 | 0.7 ng·mL−1 | [ | |
| AFP | Liver, Ovarian, Testicular Cancers | GRS/CS-CE | Square wave voltammetry | 0.05–6 ng·mL−1 | 0.02 ng·mL−1 | [ | |
| AXL | Prostate | anti-AXL/GQDs/SPCE | Differential pulse voltammetry | 1.7–1000 pg·mL−1 | 0.5 pg·mL−1 | [ | |
| CEA | Breast Colorectal and Pancreatic, Liver, Lung, Ovarian, Colon, Bladder Cancers | GOx/HRP MWCNT anti/CEA | Square wave voltammetry | 10 pg·mL−1–50 ng·mL−1 | 4.4 ± 0.1 pg·mL−1 | [ | |
| CEA | Breast Colorectal and Pancreatic, Liver, Lung, Ovarian, Colon, Bladder Cancers | Nitrogen-doped GQDs/Pt-PdBiMNP AuNPs/GCE | Amperometry | 5 fg·mL−1–50 ng·mL−1 | 2 fg·mL−1 | [ | |
| CEA | Breast Colorectal and Pancreatic, Liver, Lung, Ovarian, Colon, Bladder Cancers | Trimetallic NiAuPt NPs(GRNS/β–cyclodextrin/GONS/GCE | Amperometry | 0.001–100 ng·mL−1 | 0.27 pg·mL−1 | [ | |
| CEA | Breast Colorectal and Pancreatic, Liver, Lung, Ovarian, Colon, Bladder Cancers | AgNPs/MWCNTs/MnO2 labeled anti-CEA antibodies | Amperometry | NS | 0.03 pg·mL−1 | [ | |
| CEA | Breast Colorectal and Pancreatic, Liver, Lung, Ovarian, Colon, Bladder Cancers | Bismuth film/GCE | Square wave voltammetry | 0.05–25 ng·mL−1 | 5 pg·mL−1 | [ | |
| CEA | Breast Colorectal and Pancreatic, Liver, Lung, Ovarian, Colon, Bladder Cancers | AuNPs/poly(styrene-co-acrylic acid) microbead labeled anti-CEA antibodies | Linear sweep voltammetry | 0.5 pg·mL−1–0.5 ng·mL−1 | 0.12 pg·mL−1 | [ | |
| CEA | Breast Colorectal and Pancreatic, Liver, Lung, Ovarian, Colon, Bladder Cancers | Cd (II)/Au NPs@MWCNTs labeled anti-CEA antibodies | Square wave voltammetry | 0.01–60 ng·mL−1 | 3 pg·mL−1 CEA | [ | |
| CEA | Breast Colorectal and Pancreatic, Liver, Lung, Ovarian, Colon, Bladder Cancers | PtPNPs/Cd(II) labeled anti-CEA antibodies | Amperometry | 0.05–200 ng·mL−1 | 0.002 ng·mL−1 CEA | [ | |
| CAS | Bladder Cancer | Bismuth film-modified nylon membrane-foldable SPCE | Square wave voltammetry | 0–5 µg·mL−1 CAS | 0.04 µg·mL−1 CAS | [ | |
| CEA | Breast Colorectal and Pancreatic, Liver, Lung, Ovarian, Colon, Bladder Cancers | 4-electrode SPCE array | Differential pulse voltammetry | 0.16–9.2 ng·mL CEA | 0.04 ng·mL−1 CEA | [ | |
| HER2-ECD | Breast Cancer | SPCE-AuNPs | Square wave voltammetry | 0–50 ng·mL−1 (HER2-ECD) | 2.9 ng·mL−1 | [ | |
| IL-6 | Rheumatoid Arthritis | Poly-HRP labeled anti-IL-6 antibodies | Amperometry | 10–1300 fg·mL−1 | 10 fg·mL−1 | [ | |
| IL-6 | Rheumatoid Arthritis | HRP labeled anti-IL-6 antibodies | Amperometry | 20–400 pg·mL−1 | 20 pg·mL−1 | [ | |
| IL-6 | Rheumatoid arthritis | HRP/MWCNT labeled anti-IL-6 antibodies | Amperometry | NS | 0.5 pg·mL−1 | [ | |
| PSA | Prostate | Silver hybridized mesoporous silica nanoparticles | Amperometry | 0.15–20 ng·mL−1 | 0.06 ng·mL−1 | [ | |
| PSA | Prostate | Multi-HRP/MWCNT labeled anti-PSA antibodies | Amperometry | NS | [ | ||
| PSA | Prostate | AuNPs/PAMAM/HRP labeled PSA aptamer | Electrochemical impedance spectroscopy | 5 pg·mL−1–35 ng·mL−1 | 5 pg·mL−1 | [ | |
| PSA | Prostate | Au/Ag-graphene oxide/GQDs labeled anti-PSA antibodies | Electrochemiluminescent | 1 pg·mL−1–10 ng·mL−1 | 0.29 pg·mL−1 | [ | |
| PSA | Prostate | HRP-modified magnetic particles labeled anti-PSA antibodies | Amperometry | 4–10 ng·mL−1 | 0.5 pg·mL−1 | [ | |
| PSA | Prostate | Anti-PSA/MWCNTs/IL/GCE | Differential pulse voltammetry | 0.2–1.0 ng·mL−1 | 20 pg·mL−1 | [ | |
| PSA | Prostate | AuNPs-microfluidic 8-electrode SPCE array | Amperometry | 0.23 pg·mL−1 PSA | [ | ||
| PSA | Prostate Cancer | Porous membrane-coated | Amperometry | NS | 0.4 µg L−1 PSA | [ | |
| PSA | Prostate | 16-electrode SPCE array | Amperometry | - | 5 pg·mL−1 PSA | [ | |
| PthA | Citrus Bacterial Cancer Disease | AuNP/PB/CILE/GCE | Square wave voltammetry | 0.03–100 nM | 0.01 nM | [ | |
| TNF-α | Rheumatoid Arthritis | PA+PAA/GCE | Amperometry | 0.02–200.00 ng·mL−1 | 0.01 ng·mL−1 | [ | |
| TNF-α | Rheumatoid Arthritis | K3[Fe(CN)6]-CHT/GA/NA/mouse anti-human TNF-α | Cyclic voltammetry | 0.02–34 ng·mL−1 | 10 pg·mL−1 | [ | |
| TNF-α | Rheumatoid Arthritis | C60-fMWCNT-IL | Differential pulse voltammetry | 5.0–75 pg·mL−1 | 2.0 pg·mL−1 | [ | |
| TNF-α | Rheumatoid Arthritis | Microfluidic | Differential pulse voltammetry | 3.25–50 ng·mL−1 | 4.1 ng·mL−1 | [ | |
| TNF-α | Rheumatoid Arthritis | Dibutyl phthalate/polyvinyl chloride matrix | Potentiometry | 0.1–1.0 mg·L−1 | 0.015 mg·L−1 | [ | |